Garrett K Berger1, Ali McBride1, Stephanie Lawson1, Kelsey Royball1, Seongseok Yun2, Kevin Gee3, Irbaz Bin Riaz2, Ahlam A Saleh4, Soham Puvvada2, Faiz Anwer5. 1. College of Pharmacy, University of Arizona, Tucson, AZ, 85721, United States. 2. Departments of Medicine, University of Arizona, Tucson, AZ, 85721, United States. 3. College of Medicine, University of Arizona, Tucson, AZ, 85721, United States. 4. University of Arizona Health Sciences Library, University of Arizona, Tucson, AZ 85721, United States. 5. Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States. Electronic address: anwerf@email.arizona.edu.
Abstract
BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL. OBJECTIVE: Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30+ malignancies in humans. DATA SOURCES: We searched various databases including PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015). ELIGIBILITY CRITERIA: Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered. INCLUDED STUDIES: A total of 28 articles met these criteria and are summarized in this manuscript. CONCLUSION: Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30+ malignancies.
BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL. OBJECTIVE: Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30+ malignancies in humans. DATA SOURCES: We searched various databases including PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015). ELIGIBILITY CRITERIA: Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered. INCLUDED STUDIES: A total of 28 articles met these criteria and are summarized in this manuscript. CONCLUSION: Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30+ malignancies.
Authors: Nikolaos Patsinakidis; Alexander Kreuter; Rose K C Moritz; Markus Stücker; Peter Altmeyer; Katrin Möllenhoff Journal: Acta Derm Venereol Date: 2015-02 Impact factor: 4.437
Authors: Josephine A Taverna; Seongseok Yun; Jayasree Jonnadula; Ahlam Saleh; Irbaz Bin Riaz; Ivo Abraham; Andrew M Yeager; Daniel O Persky; Ali McBride; Subrata Haldar; Faiz Anwer Journal: Biol Blood Marrow Transplant Date: 2016-02-16 Impact factor: 5.742
Authors: Nancy L Bartlett; Robert Chen; Michelle A Fanale; Pauline Brice; Ajay Gopal; Scott E Smith; Ranjana Advani; Jeffrey V Matous; Radhakrishnan Ramchandren; Joseph D Rosenblatt; Dirk Huebner; Pamela Levine; Laurie Grove; Andres Forero-Torres Journal: J Hematol Oncol Date: 2014-03-19 Impact factor: 17.388
Authors: Earl F Albone; Jared L Spidel; Xin Cheng; Young Chul Park; Sara Jacob; Andrew Z Milinichik; Ben Vaessen; Janet Butler; J Bradford Kline; Luigi Grasso Journal: Cancer Biol Ther Date: 2017-04-10 Impact factor: 4.742
Authors: Lei Huang; Ruiqin Wang; Kun Xie; Jingming Zhang; Fei Tao; Chenyu Pi; Yan Feng; Hua Gu; Jianmin Fang Journal: Breast Cancer Res Treat Date: 2021-10-16 Impact factor: 4.872
Authors: Alejandro A Gru; Jinah Kim; Melissa Pulitzer; Joan Guitart; Maxime Battistella; Gary S Wood; Lorenzo Cerroni; Werner Kempf; Rein Willemze; Joya Pawade; Christiane Querfeld; Andras Schaffer; Laura Pincus; Michael Tetzlaff; Madeleine Duvic; Julia Scarisbrick; Pierluigi Porcu; Aaron R Mangold; David J DiCaudo; Michi Shinohara; Eric K Hong; Bethany Horton; Youn H Kim Journal: Am J Surg Pathol Date: 2018-06 Impact factor: 6.298